基于影像组学的异质性对现有风险标准预测肝细胞癌肝移植后复发的增量价值
多中心队列纳入196例肝细胞癌肝移植患者,构建CT影像组学特征并联合米兰、UCSF、Metro-Ticket 2.0和杭州标准建立列线图;联合模型在训练集和测试集的C指数均高于原标准,且临床净获益更高。
要点
- CT影像组学特征与肝移植后无复发生存显著相关,在原风险标准各亚组中亦相关。
- 联合影像组学特征后,四个列线图的C指数均高于对应的现有风险标准。
- 联合模型较现有标准具有更高的临床净获益。
核心结论
- 基于影像组学的瘤内异质性可预测肝细胞癌肝移植后结局,并为现有风险标准提供增量价值。
研究设计与样本
- 多中心队列研究,纳入196例肝细胞癌肝移植患者,构建基于CT的影像组学特征,终点为肝移植后无复发生存。
诊断标准与关键数值
- 影像组学特征在训练集和测试集均与无复发生存显著相关;联合列线图C指数:R-Milan 训练集0.745、测试集0.765 vs 米兰标准0.677;R-UCSF 0.748/0.767 vs UCSF标准0.675;R-Metro-Ticket 2.0 0.756/0.783 vs Metro-Ticket 2.0标准0.670;R-Hangzhou 0.751/0.760 vs 杭州标准0.691。
临床应用与阅片要点
- 作者认为将基于影像组学的瘤内异质性纳入肝细胞癌风险标准,可能有助于候选者选择、监测和辅助试验设计。
局限性
- 米兰、UCSF、Metro-Ticket 2.0和杭州标准在预测肝移植后结局方面可能不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: The aim of the study was to evaluate the association between the radiomics-based intratumoral heterogeneity (ITH) and the recurrence risk in hepatocellular carcinoma (HCC) patients after liver transplantation (LT), and to assess its incremental to the Milan, University of California San Francisco (UCSF), Metro-Ticket 2.0, and Hangzhou criteria.
METHODS: A multicenter cohort of 196 HCC patients were investigated. The endpoint was recurrence-free survival (RFS) after LT. A CT-based radiomics signature (RS) was constructed and assessed in the whole cohort and in the subgroups stratified by the Milan, UCSF, Metro-Ticket 2.0, and Hangzhou criteria. The R-Milan, R-UCSF, R-Metro-Ticket 2.0, and R-Hangzhou nomograms which combined RS and the four existing risk criteria were developed respectively. The incremental value of RS to the four existing risk criteria in RFS prediction was evaluated.
RESULTS: RS was significantly associated with RFS in the training and test cohorts as well as in the subgroups stratified by the existing risk criteria. The four combined nomograms showed better predictive capability than the existing risk criteria did with higher C-indices (R-Milan [training/test] vs. Milan, 0.745/0.765 vs. 0.677; R-USCF vs. USCF, 0.748/0.767 vs. 0.675; R-Metro-Ticket 2.0 vs. Metro-Ticket 2.0, 0.756/0.783 vs. 0.670; R-Hangzhou vs. Hangzhou, 0.751/0.760 vs. 0.691) and higher clinical net benefit.
CONCLUSIONS: The radiomics-based ITH can predict outcomes and provide incremental value to the existing risk criteria in HCC patients after LT. Incorporating radiomics-based ITH in HCC risk criteria may facilitate candidate selection, surveillance, and adjuvant trial design.
KEY POINTS: • Milan, USCF, Metro-Ticket 2.0, and Hangzhou criteria may be insufficient for outcome prediction in HCC after LT. • Radiomics allows for the characterization of tumor heterogeneity. • Radiomics adds incremental value to the existing criteria in outcome prediction.
引用
- Nie P, Zhang J, Miao W, et al. Incremental value of radiomics-based heterogeneity to the existing risk criteria in predicting recurrence of hepatocellular carcinoma after liver transplantation. Eur Radiol. 2023. PMID: 37012548. doi:10.1007/s00330-023-09591-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。